Recombinant monoclonal antibody to ERBB2. Pertuzumab (also called 2C4, trade name pertuzumab) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.
Figure 1 Pertuzumab enhanced degradation of ErbB3 in cells expressing high levels of ErbB2. (A) PAE.EGFR.ErbB3, MCF-7, PAE.
ErbB3 and SK-BR-3 cells were preincubated with or without 25 µg/ml pertuzumab (100 µg/ml for SK-BR-3 cells) for 1 h at 37°C. Cells were then incubated with or without CHX (25 µg/ml)) either without ligand, or with 10 nM HRG- β1 ECD, with or without pertuzumab, for 8 h at 37°C. The cells were lysed and subjected to western blotting using rabbit anti-ErbB3 and anti-tubulin (loading control) antibodies. This figure demonstrates one representative experiment out of a minimum of three. (B) Net luminescence values of bands corresponding to ErbB3 were quantified, normalized to the loading control. The average values of minimum three independent experiments ± standard deviation were plotted as percentage of control without CHX (indicated by the stippled line). Statistical analysis was performed and significant differences are indicated by asterisks (*). Single asterisk indicates P < 0.05, double asterisk indicates P < 0.01.
Sak, M. M., Szymanska, M., Bertelsen, V., Hasmann, M., Madshus, I. H., & Stang, E. (2013). Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis, 34(9), 2031-2038.
Figure 2 Pertuzumab enhances EGF-induced internalization of EGFR in cells expressing EGFR and ErbB2.
PAE cells stably expressing EGFR alone or EGFR and ErbB2 (A) and SKBr3 cells (B) were incubated with or without pertuzumab (25 μg/mL) for 1 h at 37°C and subsequently with 1 ng/mL 125 I-EGF at 37°C for the times indicated. The ratio of internalized to surface-localized 125 I-EGF was plotted as a function of time. Mean ± SE of three independent experiments with four parallels.
Hughes, J. B., Berger, C., Rødland, M. S., Hasmann, M., Stang, E., & Madshus, I. H. (2009). Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Molecular cancer therapeutics, 1535-7163.
Figure 3 Pertuzumab doesnot affect EGF internalization inPAE cells expressing EGFR onlybut rescues EGF internalizationin PAE cell.
A,PAE.EGFR andPAE.EGFR.ErbB2 cells were incu-batedwithAlexa555-EGF(60 ng/mL) for 15 min at 37°C.The cells were fixed and immu-nostained using rabbit anti-EEA1antibody followed by Alexa 647-conjugated donkey anti-rabbitantibody.B,PAE.EGFR and PAE.EGFR.ErbB2cellswereincubatedwith pertuzumab (25μg/mL) for1 h at 37°C followed by Alexa555-EGF (60 ng/mL) for 15 minat 37°C and subsequently fixedand stained as described inA.Endocytosed EGF is observed tocolocalize with EEA1 in early en-dosomes (pinkdots).
Hughes, J. B., Berger, C., Rødland, M. S., Hasmann, M., Stang, E., & Madshus, I. H. (2009). Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Molecular cancer therapeutics, 1535-7163.
Figure 4 Impact of therapeutics on EGF-induced fast signaling.
Data show EGF-induced ERK1/2 (a and c) and AKT (b and d) phosphorylation after preincubation of SKBR3 cells with trastuzumab, pertuzumab or erlotinib (a and b), as well as with all possible combinations (c and d). Phosphorylation dynamics were analyzed by RPPA. EGF (5 nM) induced phosphorylation of AKT and ERK1/2 in serum-starved SKBR3 cells. Pertuzumab and trastuzumab downregulated AKT signaling, whereas erlotinib, applied alone and in all combinations with therapeutic antibodies, inhibited the activation of both the pathways. Corresponding data set for HCC1954 cells is shown as Supplementary Figure S3 and Supplementary Table S1.
Henjes, F., Bender, C., Von Der Heyde, S., Braun, L., Mannsperger, H. A., Schmidt, C., ... & Korf, U. (2012). Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis, 1(7), e16.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to ERBB2. Pertuzumab (also called 2C4, trade name pertuzumab) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B008(A) | Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] | IF, FC, FuncS | scFv-(D-Arg)9 |
IAB-B008(G) | Recombinant Anti-human ERBB2 Intrabody [+36 GFP] | WB, ICC, FuncS | scFv-(+36GFP) |
IAB-B008(T) | Recombinant Anti-human ERBB2 Intrabody [Tat] | ICC, Neut, FuncS | scFv-Tat |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-005 | Anti-Human ErbB2 Recombinant Antibody (Trastuzumab) | FC, IP, ELISA, Neut, FuncS, IF, IHC | IgG1 - kappa |
TAB-H70 | Anti-Human ERBB2 Recombinant Antibody (Trastuzumab Emtansine) | ELISA, IP, FC, FuncS, Neut, IF, ICC | IgG1 - kappa |
TAB-033CT-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-033CT-F(E)) | ELISA, WB | Humanized Fab |
TAB-038CT-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-038CT-F(E)) | WB | Humanized Fab |
TAB-039CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (h1E11) | WB | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-761 | Anti-ERBB2 Recombinant Antibody (Margetuximab) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
TAB-049CT | Anti-Human HER2/neu Recombinant Antibody (ChA21) | IHC, Inhib, WB, Activ, FC | Chimeric antibody (mouse/human) |
TAB-049CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
TAB-049CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G022E | Anti-ERBB2 immunotoxin 4D5 (scFv)-PE | Cytotoxicity assay, Function study | |
AGTO-G022D | Anti-ERBB2 immunotoxin 4D5 (scFv)-DT | Cytotoxicity assay, Function study | |
AGTO-G022G | Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel | Cytotoxicity assay, Function study | |
AGTO-G022R | Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA | Cytotoxicity assay, Function study | |
AGTO-G022S | Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
PNBL-066 | Recombinant Anti-HER2 VHH Single Domain Antibody (Gr3) | SPR | Llama VHH |
PNBL-067 | Recombinant Anti-HER2 VHH Single Domain Antibody (Gr6) | SPR | Llama VHH |
PNBL-069 | Recombinant Anti-HER2 VHH Single Domain Antibody (huMAb4D5-5) | ELISA | Llama VHH |
TAB-032CT | Anti-Human HER2/neu Therapeutic Single Domain Antibody | WB | Single domain antibody |
HPAB-0725-YJ-VHH | Camelid Anti-ERBB2 Recombinant Single Domain Antibody (SR-87) | ELISA | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-034CT | Anti-Human HER2/neu Recombinant Antibody (pertuzumab ) | WB | |
TAB-036CT | Anti-Human HER2/neu Recombinant Antibody (6B2) | ELISA, WB | |
TAB-037CT | Anti-Human HER2/neu Recombinant Antibody (7C2/7F3) | ELISA, WB | |
TAB-034CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment (pertuzumab ) | WB | |
TAB-270CQ-S(P) | Mouse Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-270CQ-S(P)) | WB, Inhib | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-055CT | Anti-Human HER2/neu Recombinant Antibody | WB | Human antibody |
TAB-055CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment | WB | Human antibody |
TAB-056CT-S(P) | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-056CT-S(P)) | WB | Human scFv |
PABX-081 | Recombinant Human Anti-HER2 Antibody (Gr3) | WB, ELISA, FuncS | IgG |
PABX-082 | Recombinant Human Anti-HER2 Antibody (Gr6) | WB, ELISA, FuncS | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-024LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Mouse antibody |
Gly-039LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-117LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Gly-118LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Mouse antibody |
Gly-145LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-146LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-147LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-177LC | Recombinant Anti-Human ERBB2 Antibody (Non-glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0195MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0695MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0779MZ | Chicken Anti-ErbB2 Polyclonal IgY | ICC, IF, IHC, IP | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-737CQ | Mouse Anti-ERBB2 Recombinant Antibody (clone 7.16.4) | Block, IP, IF, FC | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1178 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone DS1178AB) | IHC-P, IHC-Fr | Rabbit IgG |
MOR-4586 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH99DS) | WB | Rabbit IgG |
MOR-4587 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH100DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0091-FY | Human Anti-ERBB2 Recombinant Antibody (clone MIL12) | ELISA | Humanized IgG |
HPAB-0608LY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0608LY) | ELISA, Inhib, WB, FC | Humanized IgG1 |
HPAB-0609LY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0609LY) | ELISA, Inhib | Humanized IgG1 |
HPAB-0610LY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0610LY) | ELISA, Inhib | Humanized IgG1 |
PABC-447 | Human Anti-ERBB2 Recombinant Antibody (clone 39S) | ELISA, FuncS | Human IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0733LY-F(E) | Human Anti-ERBB2 Recombinant Antibody (clone AH06); Fab Fragment | ELISA | Human Fab |
HPAB-0734LY-F(E) | Human Anti-ERBB2 Recombinant Antibody (clone A058); Fab Fragment | ELISA | Human Fab |
HPAB-0735LY-F(E) | Human Anti-ERBB2 Recombinant Antibody (clone AH16); Fab Fragment | ELISA | Human Fab |
HPAB-0736LY-F(E) | Human Anti-ERBB2 Recombinant Antibody (clone A091); Fab Fragment | ELISA | Human Fab |
HPAB-1111LY-F(E) | Mouse Anti-ERBB2 Recombinant Antibody; Fab Fragment (HPAB-1111LY-F(E)) | ELISA | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-468CQ | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Timigutuzumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-053 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-761 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Margetuximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-005 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Trastuzumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0170JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6VLF); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0171JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6L1); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0172JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H2); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0173JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H211); scFv Fragment | ELISA, FuncS | Human scFv |
PSBS-0070 | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (PSBS-0070) | ELISA, FuncS | Human scFv |
There are currently no Customer reviews or questions for TAB-053. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.